slides · global inventory
Table
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 60,568
Current window 40,681-40,710
Pages 2,019
Rows per page 30
Component
40,681-40,710 of 60,568
31
The footer explicitly notes the absence of Serious Adverse Events (SAEs), infections, or events leading to discontinuation.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
32
Data presented as mean change from baseline with 90% CI. Includes table of mean values for delta QTc and absolute QTc.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
35
The diagram illustrates the signaling pathways (TLR, IL-1R, B Cell Receptor) and the specific points of intervention (red asterisks) for the therapy.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
36
The slide presents two charts: a tumor growth inhibition curve and a PK/PD correlation chart showing drug concentration vs. target degradation over time.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
37
The slide outlines a clinical trial design using a dose-escalation process leading to MTD/RP2D expansion cohorts.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
38
Data presented for Cycle 1; DL4 shows mean values for n=2 patients.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
39
Includes a disclaimer/footnote regarding patient population and MYD88 mutation status.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
42
Includes a table of prevalence/incidence for specific oncology indications and a biological pathway diagram.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
44
The slide outlines a standard oncology clinical trial design (3+3 or similar dose escalation) followed by cohort expansion.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
45
Clinical trial safety data table showing patient counts and percentages for specific adverse events.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
46
Includes a line chart for PK profiles and a table for PK parameters (Cmax, AUClast, Vd, CL, t1/2).Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
47
The slide presents clinical trial results for KT-333, comparing degradation percentages across three dose levels (DL1, DL2, DL3) over two cycles.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
53
Includes a table comparing clinical stage and potency metrics (IC50, DC50) across multiple competitors.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
57
The slide title mentions KT-333, but the content refers to KT-253 throughout; this is likely a typo in the source deck.Kymera | Investor Presentation Deck | 60 slides · Kymera
Pitch deck Investor relations 1 hit
30
Limoneira | Investor Day Presentation Deck | 65 slidesLimoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Satisfaction1 hit
40
Limoneira | Investor Day Presentation Deck | 65 slidesLimoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Satisfaction1 hit
41
The slide highlights the discrepancy between book value and market value for real estate and agricultural assets.Limoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Action1 hit
46
The slide uses a mix of historical performance data and forward-looking revenue projections to justify the monetization strategy.Limoneira | Investor Day Presentation Deck | 65 slides · Limoneira
Conference presentation Investor relations Beat · Action1 hit
06
The slide uses a color-coded table structure to map commitments to specific programs and initiatives.LVMH | ESG Presentation Deck | 33 slides · LVMH
Conference presentation Investor relations Beat · WhyLoop · Cost Of Inaction1 hit
08
The slide uses a structured table format to track ESG progress against specific time-bound goals.LVMH | ESG Presentation Deck | 33 slides · LVMH
Conference presentation Investor relations Beat · KPIs and TargetsLoop · Cost Of Inaction1 hit
14
The slide uses a concentric circle diagram to illustrate Scope 1+2 vs Scope 3 emissions, with a supporting table for business group breakdown.LVMH | ESG Presentation Deck | 33 slides · LVMH
Conference presentation Investor relations Beat · KPIs and TargetsLoop · Cost Of Inaction1 hit
17
The slide uses a grid layout to map strategic pillars to specific KPIs, year-over-year changes, targets, and associated corporate programs.LVMH | ESG Presentation Deck | 33 slides · LVMH
Conference presentation Investor relations Beat · Key MessagesLoop · So What Cascade1 hit
16
The table shows growth percentages across various time horizons for key financial metrics like Total Assets, DNII, Dividends, and NAV per share.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · SolutionLoop · Golden Circle1 hit
25
Includes two tables comparing GAAP ROE and two bar charts showing historic average GAAP ROE and implied credit gains.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · Market Size1 hit
35
The table compares 5-year total economic benefit and management costs for MAIN vs various peer group quartiles.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · TeamLoop · Cost Of Inaction1 hit
36
The table compares internal vs external management structures and their associated costs relative to economic benefits generated over a 5-year period.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · TeamLoop · Cost Of Inaction1 hit
37
The table highlights that Main Street Capital uses an internal management structure, which correlates with a lower percentage of economic profits paid to management compared to most external-managed peers.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · TeamLoop · Cost Of Inaction1 hit
38
The table compares Main Street Capital Corporation against various peer group segments (Average, Top 10%, Top/Middle/Bottom Quartiles) across multiple financial metrics.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · TeamLoop · Cost Of Inaction1 hit
39
The table highlights Main Street's performance metrics against 14 other BDCs over a 6-year period (2017-2022).Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · TeamLoop · Cost Of Inaction1 hit
40
The table highlights Main Street's performance metrics (dividends, CAGR, coverage) against 14 other BDCs.Main Street Capital | Investor Day Presentation Deck | 155 slides · Main Street Capital Corporation
Conference presentation Investor relations Beat · TeamLoop · Cost Of Inaction1 hit